China Shineway Pharmaceutical Group Inkomsten in het verleden
Verleden criteriumcontroles 5/6
China Shineway Pharmaceutical Group is de winst gegroeid met een gemiddeld jaarlijks percentage van 20.8%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 5.7%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 13.4% per jaar. Het rendement op eigen vermogen van China Shineway Pharmaceutical Group is 15.1%, en het heeft een nettomarge van 26.3%.
Belangrijke informatie
20.8%
Groei van de winst
21.6%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 5.6% |
Inkomstengroei | 13.4% |
Rendement op eigen vermogen | 15.1% |
Nettomarge | 26.3% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
China Shineway Pharmaceutical Group Limited's (HKG:2877) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Oct 18If EPS Growth Is Important To You, China Shineway Pharmaceutical Group (HKG:2877) Presents An Opportunity
Jun 03Is China Shineway Pharmaceutical Group (HKG:2877) A Risky Investment?
May 13China Shineway Pharmaceutical Group (HKG:2877) Has Announced That It Will Be Increasing Its Dividend To CN¥0.461
Apr 26Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 41%?
Apr 17China Shineway Pharmaceutical Group (HKG:2877) Is Increasing Its Dividend To CN¥0.461
Mar 31China Shineway Pharmaceutical Group Limited's (HKG:2877) 26% Price Boost Is Out Of Tune With Earnings
Mar 14Does China Shineway Pharmaceutical Group (HKG:2877) Deserve A Spot On Your Watchlist?
Jan 29China Shineway Pharmaceutical Group (HKG:2877) Seems To Use Debt Rather Sparingly
Sep 28China Shineway Pharmaceutical Group (HKG:2877) Is Paying Out A Dividend Of CN¥0.118
Sep 01We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease
Aug 03Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 44%?
May 30We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease
Mar 07China Shineway Pharmaceutical Group's (HKG:2877) Dividend Will Be Reduced To CN¥0.125
Sep 01China Shineway Pharmaceutical Group Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 31China Shineway Pharmaceutical Group (HKG:2877) Has A Rock Solid Balance Sheet
Apr 07China Shineway Pharmaceutical Group's(HKG:2877) Share Price Is Down 55% Over The Past Three Years.
Mar 11Should You Buy China Shineway Pharmaceutical Group Limited (HKG:2877) For Its Dividend?
Feb 18Should You Use China Shineway Pharmaceutical Group's (HKG:2877) Statutory Earnings To Analyse It?
Jan 31Is China Shineway Pharmaceutical Group Limited (HKG:2877) Trading At A 49% Discount?
Jan 13What Is The Ownership Structure Like For China Shineway Pharmaceutical Group Limited (HKG:2877)?
Dec 25We Think China Shineway Pharmaceutical Group (HKG:2877) Can Manage Its Debt With Ease
Dec 10Reflecting on China Shineway Pharmaceutical Group's (HKG:2877) Share Price Returns Over The Last Five Years
Nov 25Opbrengsten en kosten
Hoe China Shineway Pharmaceutical Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 4,205 | 1,105 | 2,111 | 107 |
31 Mar 24 | 4,361 | 1,037 | 2,212 | 109 |
31 Dec 23 | 4,517 | 970 | 2,314 | 110 |
30 Sep 23 | 4,525 | 926 | 2,318 | 124 |
30 Jun 23 | 4,534 | 883 | 2,323 | 137 |
31 Mar 23 | 4,242 | 803 | 2,215 | 127 |
31 Dec 22 | 3,951 | 723 | 2,107 | 117 |
30 Sep 22 | 3,718 | 651 | 2,004 | 117 |
30 Jun 22 | 3,485 | 579 | 1,902 | 116 |
31 Mar 22 | 3,354 | 568 | 1,832 | 115 |
31 Dec 21 | 3,224 | 557 | 1,763 | 113 |
30 Sep 21 | 3,122 | 453 | 1,676 | 109 |
30 Jun 21 | 3,020 | 350 | 1,590 | 105 |
31 Mar 21 | 2,838 | 322 | 1,528 | 102 |
31 Dec 20 | 2,656 | 295 | 1,466 | 100 |
30 Sep 20 | 2,592 | 382 | 1,425 | 88 |
30 Jun 20 | 2,528 | 469 | 1,384 | 77 |
31 Mar 20 | 2,617 | 486 | 1,393 | 90 |
31 Dec 19 | 2,706 | 503 | 1,402 | 103 |
30 Sep 19 | 2,670 | 520 | 1,367 | 102 |
30 Jun 19 | 2,633 | 537 | 1,332 | 100 |
31 Mar 19 | 2,602 | 521 | 1,293 | 114 |
31 Dec 18 | 2,570 | 506 | 1,254 | 128 |
30 Sep 18 | 2,492 | 516 | 1,174 | 136 |
30 Jun 18 | 2,413 | 526 | 1,095 | 144 |
31 Mar 18 | 2,166 | 489 | 929 | 120 |
31 Dec 17 | 1,920 | 452 | 763 | 97 |
30 Sep 17 | 1,897 | 474 | 708 | 81 |
30 Jun 17 | 1,873 | 496 | 653 | 66 |
31 Mar 17 | 1,933 | 542 | 651 | 70 |
31 Dec 16 | 1,993 | 589 | 648 | 74 |
30 Sep 16 | 1,935 | 569 | 659 | 79 |
30 Jun 16 | 1,877 | 549 | 669 | 84 |
31 Mar 16 | 1,966 | 603 | 673 | 76 |
31 Dec 15 | 2,055 | 658 | 678 | 69 |
30 Sep 15 | 2,147 | 672 | 691 | 73 |
30 Jun 15 | 2,239 | 685 | 705 | 78 |
31 Mar 15 | 2,234 | 695 | 701 | 79 |
31 Dec 14 | 2,229 | 705 | 697 | 80 |
30 Sep 14 | 2,228 | 704 | 697 | 79 |
30 Jun 14 | 2,227 | 703 | 698 | 78 |
31 Mar 14 | 2,207 | 693 | 699 | 81 |
31 Dec 13 | 2,187 | 684 | 701 | 83 |
Kwaliteitswinsten: 2877 heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (26.3%) 2877 } zijn hoger dan vorig jaar (19.5%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van 2877 is de afgelopen 5 jaar aanzienlijk gegroeid met 20.8% per jaar.
Versnelling van de groei: De winstgroei van 2877 over het afgelopen jaar ( 25.1% ) overtreft het 5-jarig gemiddelde ( 20.8% per jaar).
Winst versus industrie: De winstgroei 2877 over het afgelopen jaar ( 25.1% ) overtrof de Pharmaceuticals -sector 6.4%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 15.1% ) van 2877 wordt als laag beschouwd.